<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597621</url>
  </required_header>
  <id_info>
    <org_study_id>M/XDR_BIO_01</org_study_id>
    <nct_id>NCT02597621</nct_id>
  </id_info>
  <brief_title>Biomarkers for Therapy Response in Drug-resistant Tuberculosis</brief_title>
  <official_title>Biomarkers for Therapy Response in Drug-resistant Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Center Borstel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Center Borstel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, observational, prospective cohort study including patients with
      multidrug-resistant tuberculosis at different sites in Germany.

      The aim the study is the identification of biomarkers for therapy response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increasing rates of multidrug-resistant (MDR) tuberculosis (TB) are causing great
      concern. The current study that will be conducted at different centers in Germany. Biomarkers
      for treatment response during the course of the tuberculosis therapy will be evaluated. The
      study will be conducted with funding of the German Center for Infection Research (DZIF).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of biomarkers for therapy response</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tuberculosis, Multidrug-resistant</condition>
  <arm_group>
    <arm_group_label>M/XDR</arm_group_label>
    <description>The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Susceptible</arm_group_label>
    <description>The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>M/XDR</arm_group_label>
    <arm_group_label>Susceptible</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with microbiologically confirmed pulmonary MDR-TB
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with confirmed pulmonary MDR-TB

          -  Subject able and willing to give informed consent

        Exclusion Criteria:

          -  HIV infection

          -  physical or mental inability preventing study participation at the discretion of the
             investigator

          -  member of a vulnerable or special population (prisoner, soldier, mentally ill, under
             guardianship)

          -  age &lt;18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Center Borstel</name>
      <address>
        <city>Borstel</city>
        <state>Schleswig-Holstein</state>
        <zip>23845</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Heyckendorf, MD</last_name>
      <phone>+49-4537-188</phone>
      <phone_ext>2901</phone_ext>
      <email>jheyckendorf@fz-borstel.de</email>
    </contact>
    <investigator>
      <last_name>Jan Heyckendorf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Lange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>October 5, 2016</last_update_submitted>
  <last_update_submitted_qc>October 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Center Borstel</investigator_affiliation>
    <investigator_full_name>Christoph Lange</investigator_full_name>
    <investigator_title>Head of International Health / Infectious Diseases, University LÃ¼beck</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

